AIDS Weekly Plus
click here to return to AIDS Weekly Plus main menu

HIV Vaccines: Weak Anti-Gag Antibodies Associated with Rapid CD4 Decline

AIDSWEEKLY Plus, 11 November 1996
Daniel J. DeNoon, Senior Editor


HIV infected individuals with weak anti-p55 antibodies are nearly eight times more likely to have rapid disease progression.

The data come from a study of Western blot reactivity patterns among U.S. Navy and Marine Corps personnel who tested positive for HIV between 1986 and 1991.

"This and a previous study [Nicholson et al., AIDS Res H, 1989;5:205] suggest that strong antibody responses to products of the gag gene are correlated with slower progression of HIV infection," wrote Frank C. Garland of the Naval Health Research Center, San Diego, California, and colleagues.

"If this association is causal rather than artifactual, then preserving the antigenic features of gag-encoded proteins might be important for candidate vaccines intended to reduce progression."

Garland et al. reported their findings in the journal Annals of Epidemiology ("Western Blot Banding Patterns of HIV Rapid Progressors in the U.S. Navy Seropositive Cohort: Implications for Vaccine Development," Ann Epidemiol, 1996;6:341-7).

From a cohort of 3414 U.S. Navy and Marine Corps personnel who tested positive for HIV, the researchers identified 325 rapid progressors. These individuals had a decline in CD4 cell count to less than 500 cells/(micro)L within one year of seroconversion.

The rapid progressors were compared to a group of 63 slower progressors, whose CD4 counts remained above 500 cells/(micro)L for at least five years after seroconversion.

The two groups were well matched for race and sex, although the rapid progressors were slightly younger and more likely to have never married.

"Rapid progressors had weaker reactivity in the anti-p55 core precursor (P<0.0001), p15 core (P<0.01), gp41 transmembrane (P<0.01,) and p31 endonuclease (P<0.05) bands on the Western blot," Garland et al. reported. "The odds ratio for rapid progressor status associated with weak or absent reactivity was 7.8 in the anti-p55 band and ranged from 2.0 to 3.2 in the anti-p31, p15, and gp41 bands."

These associations remained significant when the results were adjusted for age, race, and sex.

Garland et al. suggested several explanations for these findings:

Since the HIV gag gene is more conserved than the env surface gene, these findings provide hope for an effective HIV vaccine.

The corresponding author for this study is Frank C. Garland, Department of Health Sciences and Epidemiology, Naval Health Research Center, P.O. Box 85122, San Diego, California 92186-5122.

961111
AW961103


AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. This article first appeard in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

Copyright © 1996 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA.


AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
©1996. AEGiS.